Treatment of bladder pain syndrome and interstitial cystitis: a systematic review

被引:24
作者
Pazin, Carolina [1 ]
de Souza Mitidieri, Andreia Moreira [1 ]
Moreira Silva, Ana Paula [1 ]
Ferreira Gurian, Maria Beatriz [1 ]
Poli-Neto, Omero Benedicto [1 ]
Rosa-e-Silva, Julio Cesar [1 ]
机构
[1] Univ Sao Paulo, Fac Med, Dept Gynecol & Obstet, Av Bandeirantes 3900, BR-14049900 Ribeirao Preto, SP, Brazil
关键词
Bladder pain syndrome; Interstitial cystitis; Drug treatment; Prospective and clinical trials; TOXIN-A INJECTIONS; INTRAVESICAL HYALURONIC-ACID; PENTOSAN POLYSULFATE SODIUM; BACILLUS-CALMETTE-GUERIN; BOTULINUM-TOXIN; DOUBLE-BLIND; SYNDROME/INTERSTITIAL CYSTITIS; LASER THERAPY; EFFICACY; SYMPTOMS;
D O I
10.1007/s00192-015-2815-5
中图分类号
R71 [妇产科学];
学科分类号
100211 ;
摘要
Bladder pain syndrome/interstitial cystitis (BPS/IC) has various treatments; however, no standardized treatment has been established. The aim was to analyze different types of treatment of BPS/IC and their effectiveness. A literature review with a search strategy for articles related to BPS/IC published between 1990 and 2014 was conducted on MEDLINE, PUBMED, and SCOPUS. Only randomized controlled trials in women were included in the meta-analysis, while other experimental studies were used as bases for a systematic review of the topic. Clinical trial quality was defined according to the Jadad scale. Of 356 articles, 13 were included in the analysis. The intervention methods were as follows: instillation of hyaluronic acid, botulinum toxin A, intravesical lidocaine, hyperbaric chamber, massage, physiotherapy, phosphate-buffered saline, piroxicam in combination with doxepin, and others. We did not find any treatment with at least two randomized controlled trials for meta-analysis. Among the assessment tools for symptoms of BPS/IC, the most frequently used were the visual analogue scale, voiding record, and the O'Leary-Sant questionnaire. Existing studies were not able to define the best approach for the treatment of BPS/IC. The lack of standardized treatment may be related to the diversity of interventions used; therefore, further studies with better methodological quality are needed.
引用
收藏
页码:697 / 708
页数:12
相关论文
共 71 条
[1]  
ABEHSIRAAMAR O, 1992, J IMMUNOL, V148, P3820
[2]   The standardisation of terminology of lower urinary tract function: Report from the Standardisation Sub-committee of the International Continence Society [J].
Abrams, P ;
Cardozo, L ;
Fall, M ;
Griffiths, D ;
Rosier, P ;
Ulmsten, U ;
van Kerrebroeck, P ;
Victor, A ;
Wein, A .
AMERICAN JOURNAL OF OBSTETRICS AND GYNECOLOGY, 2002, 187 (01) :116-126
[3]  
Aghamir Seyed Mohammad Kazem, 2007, Urol J, V4, P18
[4]  
Anderson VR, 2006, DRUGS, V4, P18
[5]   Decreased sensory receptors P2X3 and TRPV1 in suburothelial nerve fibers following intradetrusor injections of botulinum toxin for human detrusor overactivity [J].
Apostolidis, A ;
Popat, R ;
Yiangou, Y ;
Cockayne, D ;
Ford, APDW ;
Davis, JB ;
Dasgupta, P ;
Fowler, CJ ;
Anand, P .
JOURNAL OF UROLOGY, 2005, 174 (03) :977-982
[6]   A placebo-controlled study of intravesical pentosanpolysulphate for the treatment of interstitial cystitis [J].
Bade, JJ ;
Laseur, M ;
Nieuwenburg, A ;
vanderWeele, LT ;
Mensink, HJA .
BRITISH JOURNAL OF UROLOGY, 1997, 79 (02) :168-171
[7]   Interstitial cystitis: Bladder training with intravesical oxybutynin [J].
Barbalias, GA ;
Liatsikos, EN ;
Athanasopoulos, A ;
Nikiforidis, G .
JOURNAL OF UROLOGY, 2000, 163 (06) :1818-1821
[8]   Prevalence of Symptoms of Bladder Pain Syndrome/Interstitial Cystitis Among Adult Females in the United States [J].
Berry, Sandra H. ;
Elliott, Marc N. ;
Suttorp, Marika ;
Bogart, Laura M. ;
Stoto, Michael A. ;
Eggers, Paul ;
Nyberg, Leroy ;
Clemens, J. Quentin .
JOURNAL OF UROLOGY, 2011, 186 (02) :540-544
[9]   SACRAL (S3) SEGMENTAL NERVE-STIMULATION AS A TREATMENT FOR URGE INCONTINENCE IN PATIENTS WITH DETRUSOR INSTABILITY - RESULTS OF CHRONIC ELECTRICAL-STIMULATION USING AN IMPLANTABLE NEURAL PROSTHESIS [J].
BOSCH, JLHR ;
GROEN, J .
JOURNAL OF UROLOGY, 1995, 154 (02) :504-507
[10]   Intravesical oxybutynin for neurogenic bladder dysfunction:: Less systemic side effects due to reduced first pass metabolism [J].
Buyse, G ;
Waldeck, K ;
Verpoorten, C ;
Björk, H ;
Casaer, P ;
Andersson, KE .
JOURNAL OF UROLOGY, 1998, 160 (03) :892-896